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Abstract
Electronic cigarettes are more and more frequently used to deliver nicotine. They are used both by the users of regular cigarettes 
and those who to date have not smoked. The literature about potential impact of electronic nicotine delivery systems on health 
is constantly growing. Particular concern is expressed about toxicity of chemical compounds and elements delivered with the 
vapour of electronic cigarettes. It turns out that products that have positive image in media, actually are not so beneficial. Fur-
thermore, they not only may cause damage to health but also death. 
Key words: electronic cigarettes, e-cigarettes, electronic nicotine delivery systems
 Adv Respir Med 2017; 85: 40–45
Introduction
Electronic cigarettes, which belong to elec-
tronic nicotine delivery systems (ENDS), are 
becoming more and more popular, superseding 
from the market regular nicotine products. Survey 
research carried out in France in 2014 showed that 
out of 15365 respondents, as many as 25.7% of 
subjects aged 15 to 75 years tried smoking elec-
tronic cigarettes [1]. 
In 2010, in Great Britain, 3–4% of smokers or 
those who quit smoking recently, used electronic 
cigarettes. In 2014, this percentage increased to 
21% [2]. It is observed that children and adoles-
cents also more frequently use ENDS. The stud-
ies conducted in the United States of America 
demonstrated that more young people were using 
ENDS than traditional tobacco products. It is es-
timated that even 29% of students of secondary 
schools smoked electronic cigarettes at least once, 
and 17–18% of them are current users of ENDS. 
The same study showed that students using ENDS 
have less factors of nicotinism risk, compared to 
people smoking regular cigarettes. The conclusion 
is that, if e-cigarettes did not exist, these people 
would not start using nicotine [3].
Therefore, the use of e-cigarettes is of great 
concern, in particular to health care authorities. 
The above presented increase in the number of 
e-cigarettes users poses questions about safety 
of their use, regarding both long- and short-term 
evaluation. It has been reflected in the PubMed 
database, in which after entering “electronic 
ciga rette” on 17 January, 2016, the list of 2505 
articles was obtained, of which in 2013, 198 
articles were reported; in 2014 — 853, and in 
2015 — as many as 1168 articles. It is difficult 
to select the most important works from such an 
abundance. The aim of this study is to help to 
understand the influence of electronic cigarettes 
on health of people using them in the light of 
recent literature findings.
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The chemical composition of electronic 
cigarettes, their toxicity and impact  
on the respiratory system
The market offers electronic cigarettes pro-
duced by various companies. The lack of stan-
dardised model of electronic cigarette hinders 
research. Different products differ in crucial qual-
ities such as electrode temperature and voltage. 
A wide choice of different flavours of e-liquids 
does not help to evaluate toxicity of the products. 
The analysis of particles in e-cigarette vapour 
showed its similar composition to regular ciga-
rettes and the reference cigarette 1R5F. The chem-
ical compounds include acetaldehyde, acrolein 
and acetone [4]. It was confirmed by the studies 
carried out by the team directed by Goniewicz. 
In addition, they discovered aromatic hydrocar-
bons, i.e. toluene and p-xylene. The analysis also 
showed the presence of the following heavy met-
als: cadmium, nickel, lead, which are also present 
in the smoke of regular cigarettes [5].
More detailed analysis of the smoke gener-
ated by electronic and regular cigarettes adds to 
the list of typical elements of tobacco smoke the 
following: sodium, iron, aluminium, potassium, 
copper, magnesium, zinc, chromium, manganese. 
The list of elements included in e-cigarette vapour 
also contains boron, silicon, calcium, sulphur, tin, 
barium, zirconium, strontium, titanium, lithium. 
It is of crucial importance as the majority of them 
have a documented adverse effect on the cells of 
the respiratory system [6].
In one study, 42 e-liquids manufactured by 
14 different producers have been examined. The 
tests were conducted among others for the pres-
ence of chemical compounds including aromat-
ic hydrocarbons. Particularly high concentra-
tion of various chemical compounds was found 
in flavoured e-liquids. It seems distressing that 
each sample contained formaldehyde whose 
concentration oscillated between 0.02 and 
10.09 mg/L and whose presence in flavoured 
e-liquids has been confirmed repeatedly. It was 
also the case with acetaldehyde, whose levels 
oscillated between 0.10 and 15.63mg/L [7]. 
Unfortunately, there are no norms or observa-
tional studies determining potential adverse 
effect of these substances on the mucous mem-
brane of the mouth and the epithelium lining 
the airways.
Diethylene glycol, which is a compound of 
proven toxic effect on the cells of the respiratory 
and nervous systems, has also been found in 
e-liquids [8].
The research in toxicity of electronic ciga-
rettes reached the point where in aerosols gener-
ated by electronic cigarettes, the concentration of 
benzaldehyde was measured. Automatic smoking 
simulator was used as a generator. The study 
included 145 available on the market e-liquids, 
and benzaldehyde was found in 108 samples. 
The highest concentration of benzaldehyde was 
detected in e-liquids with cherry flavour (5.129–
141.2 μg/30 puffs) and they were significantly 
higher compared to other flavours (p < 0.0001) [9]. 
The presence of benzaldehyde, which absorbs 
well while inspiring its vapour, may lead to such 
suffering as sore throat and cough. Negative effect 
of acrolein on epithelial cells of the respiratory 
system was proved by Sun and his team. Its toxic-
ity appears through the activation of macrophages 
to the production of reactive forms of oxygen and 
proinflammatory cytokines (TNF-a, IL-6, IL-12, 
IRF5) [10].
Using nematodes as an approved animal 
model, it was shown that e-liquids and vapour 
extracts increase oxidative stress leading to 
weaker growth of particular nematodes. Their 
reproductive capacity and vitality have been 
weakened too. It is believed that it was caused 
by propylene glycol, which is the most powerful 
inducer of the mentioned changes [11].
Other researchers confirm that consumption 
of e-cigarettes results in increased oxidative stress 
and resistance in the airways [12]. The use of 
e-cigarettes also leads to higher level of nitrogen 
oxide in exhaled air. However, there are no data 
comparing the concentration of nitrogen oxide in 
e-cigarette consumers and those smoking conven-
tional cigarettes [13].
The tests conducted on mice showed that 
exposure to e-cigarette vapour results in increased 
level of IL-6 in bronchoalveolar lavage fluid, 
which is proinflammatory cytokine. This has not 
been observed in the mice from the control group. 
Human airway epithelial cell line H292 behaves 
similarly. The levels of IL-6 and IL-8 determined 
after 16 hours from exposure to e-cigarette aerosol 
were significantly higher, compared to the con-
trol group. Contrary to IL-6, in the case of IL-8, 
dose-depending effect was not observed. It seems 
crucial that concentration of IL-8 was higher in 
the group of flavoured e-liquids [14]. Controversy 
surrounding flavoured e-cigarette solutions is evi-
denced by other researches assessing cytotoxicity 
of e-liquids. The researchers discovered relation 
between observed cytotoxicity and the level of 
chemical substances used as flavourings [15]. Fla-
vourless e-liquids, to date considered safe, were 
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examined for release of various cytokines and 
chemokines. The conducted tests proved that it is 
not the case. For the first time it has been shown 
that exposure to e-cigarette vapour free of flavour 
results in the release of the following cytokines 
and chemokines: PDGF-BB, FGF, IL-8, IL-12, IL-
17, GM-CSF, IP-10, MCP-1 and MIP-1b [16]. It has 
not been observed that short-term use of e-ciga-
rettes leads to increased concentration of IL-2, 
TNF-a, EGF, whose growth was noticed directly 
after consumption of a regular cigarette [17]. 
The effect of long-term exposure to e-cigarette 
vapour is unknown. Direct comparison of cy-
totoxicity of smoke from regular cigarettes with 
e-cigarette vapour showed smaller cytotoxicity 
of the latter. But again, flavoured e-liquid was 
the most cytotoxic in the group. It was coffee 
flavoured solution [18]. In another study, which 
also evaluated cytotoxicity of various e-liquids, 
the most distinctive was that of cinnamon and 
cookies flavour [19]. Bipolarity of e-cigarettes 
was shown by Yan and D’Ruiz who examined the 
level of nicotine in serum, the contents of carbon 
monoxide in exhaled air and cardiovascular ef-
fects in 23 subjects, who were randomly assigned 
to the group consuming electronic cigarettes 
(5 different products) and to the group using 
classic Marlboro cigarettes. The obtained data 
revealed that carbon monoxide concentration 
in exhaled air is significantly lower in the group 
of people using e-cigarettes. Other data, such as 
level of nicotine in serum are not so convincing. 
It is worth mentioning that in different periods 
of time, nicotine level frequently exceeded the 
level noted in people smoking regular cigarettes 
[20]. It was also observed that during one-hour 
e-cigarette smoking session, when the subjects 
made on average 46 puffs, the concentration of 
nicotine measured in blood of the subjects in-
creased since 5th minute of smoking and was the 
biggest when measured at the end of ad libitium 
session. Heart rate also increased in the 5th minute 
of observation and, similarly to nicotine, it persist-
ed until the end of ad libitium session [21]. While 
comparing the level of cotinine (metabolite of nic-
otine) in serum of active users of e-cigarettes with 
the consumers of regular cigarettes, it was found 
to be similar in both groups (mean concentration 
of cotinine 60.6 vs 61.3 ng/mL). The cotinine level 
in passive smokers was comparable (2.4 vs 2.6 
ng/mL). Yet these results are contradictory with 
those obtained by Van Staden. In the same study 
lung function was assessed and it was observed 
that active smoking of traditional cigarettes sig-
nificantly reduced (p < 0.001) the value of FEV1/ 
/FVC — by 7.2% on average. This fact has not been 
observed among passive smokers and e-cigarettes 
smokers [22]. Cotinine concentration in saliva of 
people using electronic nicotine delivery systems 
was similar to that found in individuals smoking 
regular cigarettes. Lower cotinine levels were 
discovered in subjects using nicotine replacement 
therapy (NRT) [23]. The important component of 
e-cigarettes is an electrode which heats up e-liq-
uid. Vapour appears when voltage exceeds 3 V and 
it is enough to produce formaldehyde, glyoxal, 
acetaldehyde and acrolein. The relation between 
the composition of vapour and ingredients used to 
produce e-liquid was discovered [24]. The quanti-
ty of nicotine generated by e-cigarettes of various 
brands is not constant. During the analysis of 20 
series at 15 puffs (it is considered that one series 
is equal to one cigarette), it was calculated that 
delivered dose of nicotine depending on the pro-
ducer amounts from 0.5 to 15.4 mg (from 0.025 
to 0.77 mg of nicotine per series). These values 
are lower than those observed during traditional 
cigarettes smoking, when it is considered that 
one cigarette delivers between 1.54 to 2.60 mg 
of nicotine [25]. However, it is worth mention-
ing that freedom to choose the place and time 
of consumption of e-cigarettes may impact the 
way and frequency of using thereof. Therefore, 
we believe that comparisons assuming the same 
model of both regular and e-cigarettes smoking 
should be treated carefully. It is possible that 
further research should go into finding the most 
frequent pattern of e-cigarettes smoking.
The impact of electronic cigarettes  
on the cardiovascular system
The authors of this paper encountered con-
tradictory studies about the influence on the 
cardiovascular system. Some researches do not 
show any influence, others list effects that may 
be hazardous to health. In 2012 Czogala et al. [26] 
did not note that e-cigarette consumption signifi-
cantly influenced blood pressure or heart rate.
Opposite conclusions were reached by Lippi 
et al. [27]. Their research has shown that using 
e-cigarettes on a regular basis results in increased 
blood pressure — in particular the diastolic one, 
tachycardia and chest pain. 
More worrying are conclusions arrived at by 
Middlekauf et al. [28] who observed adverse effect 
of e-cigarettes on the autonomic nervous system. 
These results are different from those described 
above and include hypotonia, bradycardia and 
attacks of atrial fibrillation.
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Interestingly, it has been shown that exposure 
to tobacco smoke in passive smokers in childhood 
and fetal development results in more frequent 
atrial fibrillation in adulthood [29]. Similar observa-
tions will be possibly made in the future, but for the 
time being, we have to bear in mind relatively short 
period of examination of e-cigarette consumers.
Another problem is the impact on diastolic 
function of the heart. Farsalinos et al. [30] did 
not observe the influence on diastolic function 
of the left ventricle, simultaneously showing that 
smoking one regular cigarette significantly hin-
ders this function. However, the question could 
be explored whether the lack of immediate effect 
after the vaping session equals a complete lack 
of influence on diastolic function of the heart. It 
is possible that longer exposure would lead to 
similar conclusions. 
Impact on smoking cessation
During 6 month-long observation, it has 
been shown that bigger proportion of e-cigarette 
consumers (7.3%) will not smoke traditional 
cigarettes, compared to the proportion of peo-
ple using plasters containing nicotine (5.8%) or 
e-cigarettes with placebo (4.1%) [31]. However, 
smoking cessation through replacement of regular 
cigarettes for electronic cigarettes does not seem 
to be a real success. Particularly, given that there 
is no reliable data indicating advantages of such 
behaviour. Whereas negative effects of ENDS on 
health has been confirmed. Available literature 
reports more cases of replacement of regular ciga-
rettes for the electronic ones, which, according to 
the authors of these studies, should be perceived 
as success - Caponetto et al. described among oth-
ers the cases of smoking cessation consisting in 
the above mentioned substitution by individuals 
who repeatedly tried to stop smoking using other 
available methods and who succeeded only when 
they started to use e-cigarette [32]. Some people 
claim that e-cigarettes may be more attractive as 
far as smoking cessation is concerned as they may 
have less noticeable adverse effects, compared 
to nicotine replacement therapy, and they may 
become a kind of hobby [33].
However, there is no reliable data support-
ing the theory that alternative tobacco products 
(including e-cigarettes) are a useful tool to cease 
smoking [34]. It has been confirmed by the results 
of metaanalysis conducted by Kalkhoran and 
Glantz who have found that the use of e-cigarettes 
is related to reduced chance of smoking cessation. 
They have proved that among e-cigarette con-
sumers who used e-cigarettes as the way to quit 
smoking, the proportion of those who succeeded 
was smaller by 28%, compared to the group not 
using e-cigarettes [35].
Thus, the question arises whether the change 
from addiction to cigarette smoking to depen-
dence on other sources of nicotine, may be treated 
as form of addiction treatment. From the point 
of view of psychiatrics, systematic regular con-
sumption of nicotine activates the mesolimbic 
dopaminergic pathway, giving a sense of pleasure. 
A sudden discontinuation of nicotine consump-
tion, either in the form of a cigarette or another 
one, results in abstinence symptoms. The use 
of e-cigarette in this context has to be treated as 
a form of nicotine dependence that is listed in the 
classification of psychiatric diagnoses number 
ICD-10 F17.2. A real nicotine dependence con-
sists of making the independent human reward 
effect of any form of nicotine. 
It seems that irrefutable evidence of doubt-
ful effectiveness of e-cigarettes as a useful tool 
of smoking cessation is the WHO report of 2014 
showing insufficient evidence to consider elec-
tronic cigarettes a therapeutic option [36]. 
Infrequent adverse effects and legal situation
In 2013, FDA issued statement on adverse 
effects associated with the use of e-cigarettes. It 
was assumed that conventional cigarettes are re-
sponsible for 36 types of adverse effects, whereas 
the electronic ones for 47. The effects included 
among others: exacerbation of chronic heart fail-
ure, aspiration pneumonia, second-degree burns 
on the face (due to e-cigarette explosion), chest 
pain, tachycardia, choking of e-cigarette cartridge 
by infants, migraine headaches [37]. It is particu-
larly dangerous when e-liquids are administered 
orally. For example a 5 ml cartridge of e-liquid with 
20 mg/ml nicotine concentration contains 100 mg 
of nicotine. It is estimated that a lethal dose in 
adults is 30-60 mg, and in children 10 mg [38]. The 
possibility of deliberate use of e-liquids in order to 
achieve a specific result or even death causes grave 
concern. In 2013, in Great Britain, three cases of 
intentional use of liquid nicotine in order to com-
mit suicide were reported [39]. In the Internet there 
are even instructions on how to commit suicide 
with the help of liquid nicotine [40]. The case of 
intravenous administration of e-liquid in order to 
commit suicide has been also reported [41].
Concerns about the use of e-cigarettes have 
been also voiced by the European Commission. 
Since May 2016, the market of e-liquids and 
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cartridges for e-cigarettes is governed by the Eu-
ropean Union directives (2001/83/EC; 93/42/EEC; 
2014/40/EU). Taking into account many doubts 
associated with the use and wide availability of 
these products, it seems to be a crucial forward 
step in normalising the market of electronic ciga-
rettes. There were attempts to assess the following 
aspects: information content on the label, the 
compliance of nicotine quantity with its declared 
contents, the presence of other components, the 
possibility of unintentional use by children. It has 
been shown that 40% of the examined popular 
e-liquids and e-cigarettes had not at all or out-
of-date contact data of the supplier. 76.5% of the 
analysed products have not provided information 
about nicotine as an addictive substance. 53% of 
products have not informed about possible harm-
ful effects on pregnant women and breastfeeding 
mothers. 33% of the analysed brands have not put 
on the packet information about toxicity of the con-
tents. It is required in the case when the contents of 
nicotine exceeds 1% of the solution volume. A no-
tice concerning the applied flavourings and colour 
additives has been generally limited to information 
that they are approved. There was no information 
on chemical substances used in the production 
process. Next to many discovered shortcomings, a 
good news is that only one tested product has not 
offered child-resistant fastening [42].
Conclusions
Electronic cigarettes are becoming more and 
more popular, among both the users of conven-
tional tobacco products and those who to date has 
not used any nicotine delivery systems. It seems 
that literature concerning electronic cigarettes 
is extensive but it is not the case. There are no 
studies treating in an overall manner the problem 
of harmful influence of electronic cigarettes on 
health. There are single papers that gather many 
reports and which frequently are case reports. But 
even these works raise serious doubts as to safe 
use of e-cigarettes. It seems of vital importance 
that patients should be made aware that each 
method of nicotine delivery is harmful. Follow-
ing the example of western European countries, 
nicotine dependent people should be referred to 
specialistic anti-smoking centres in order to face 
the problem with the help of an expert and not 
to the tobacco companies generating large profits 
from e-cigarettes market.
The authors do hope that the readers of this 
paper will join people combatting nicotinism, 
both its traditional and most modern variations.
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